Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study

Current Medical Research and Opinion

Volumn 27, Issue 8, 2011, Pages 1659-1668

  Athyros, Vassilios G ^a   Karagiannis, Asterios ^a   Ganotakis, Emmanouel S ^b   Paletas, Konstantinos ^a   Nicolaou, Vassilios ^c   Bacharoudis, George ^d   Tziomalos, Konstantinos ^a   Alexandrides, Theodore ^e   Liberopoulos, Evangelos N ^f   Mikhailidis, Dimitri P ^g  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c RED CROSS HOSPITAL   (Greece)

^d Primary Prevention Unit Alexandroupolis   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

^f UNIVERSITY OF IOANNINA   (Greece)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular events; Metabolic syndrome; Multifactorial treatment; Renal function; Serum uric acid

Indexed keywords

AMLODIPINE; ATORVASTATIN; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; QUINAPRIL; TETRAHYDROLIPSTATIN; URIC ACID;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG DOSE INCREASE; EVENT FREE SURVIVAL; EXERCISE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; STUDENT T TEST; URIC ACID BLOOD LEVEL;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DISEASE-FREE SURVIVAL; FEMALE; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; URIC ACID;

EID: 79960430739     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.595782     Document Type: Article

References (56)

1. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18. (Pubitemid 26012498)
2. Pinto-Sietsma S-J, Navis G, Janssen WMT, et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003;41:733-41. (Pubitemid 36401550)
3. Beddhu S, Kimmel PL, Ramkumar N, et al. Associations of metabolic syndrome with inflammation in CKD: results from the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2005;46:577-86. (Pubitemid 41383935)
4. Crook ED, Thallapureddy A, Migdal S, et al. Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? Am J Med Sci 2003;325:340-8. (Pubitemid 36712656)
5. Straznicky NE, Grima MT, Lambert EA, et al. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J Hypertens 2011;29:553-64.
6. Ninomiya T, Kiyohara Y, Kubo M, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 2006; 48:383-91. (Pubitemid 44247252)
7. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. Ann Intern Med 2004; 140:167-74.
8. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16:2134-40. (Pubitemid 41716445)
9. Nitta K. Possible link between metabolic syndrome and chronic kidney disease in the development of cardiovascular disease. Cardiol Res Pract 2011; 2011:963517.
10. Tuttle KR. Renal manifestations of the metabolic syndrome. Nephrol Dial Transplant 2005;20:861-4. (Pubitemid 40704018)
11. Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006;55:1293-301. (Pubitemid 44354944)
12. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-97. (Pubitemid 35386908)
13. Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:12-17. (Pubitemid 34066579)
14. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-10. (Pubitemid 30257539)
15. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112: 2735-52. (Pubitemid 41532612)
16. Chimonas T, Karagiannis A, Athyros VG, et al. Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis. Metab Syndr Relat Disord 2010;8:523-9.
17. Chimonas T, Athyros VG, Ganotakis E, Chimonas T, Karagiannis A, Athyros VG.; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. Angiology 2010;61:49-57.
18. Athyros VG, Ganotakis E, Kolovou G, et al.; for the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT). A prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011; in press.
19. Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007;24:1160-3. (Pubitemid 47437878)
20. Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;25:CD002967.
21. Athyros VG, Karagiannis A, Hatzitolios AI, et al. SAGE-METS collaborative group. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin 2009; 25:971-80.
22. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-85. (Pubitemid 15087125)
23. Leoncini G, Viazzi F, Pontremoli R. Chronic kidney disease and albuminuria in arterial hypertension. Curr Hypertens Rep 2010;12:335-41.
24. Dalrymple LS, Kaysen GA. The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol 2008;28:723-31.
25. Brancati FL, Whelton PK, Randall BL, et al. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997;278:2069-74. (Pubitemid 28016228)
26. de Jong PE, Verhave JC, Pinto-Sietsma SJ, et al. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002;26(Suppl 4):S21-4. (Pubitemid 36071967)
27. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69. (Pubitemid 37337595)
28. Navaneethan SD, Pansini F, Perkovic V, et al. HMGCoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007784. DOI: 10.1002/14651858.CD007784.
29. US Renal Data System. USRDS 2006 Annual data report, part 2: incidence and prevalence. Available at: www.usrds.org/adr-2006.htm. Accessed April 14, 2011.
30. Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-16. (Pubitemid 44036185)
31. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112:171-8. (Pubitemid 40982298)
32. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
33. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34. (Pubitemid 38901488)
34. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27. (Pubitemid 46050336)
35. Athyros VG, Mitsiou EK, Tziomalos K, et al. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother 2010;11:723-30.
36. Athyros VG, Karagiannis A, Kakafika A, et al. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant 2007; 22:963-4. (Pubitemid 46351732)
37. Shepherd J, Kastelein JJ, Bittner V, et al. Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-9.
38. Shepherd J, Kastelein JJ, Bittner V, et al. TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-54. (Pubitemid 351471787)
39. Colhoun HM Betteridge DJ, Durrington PN, et al., and CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009;54:810-19.
40. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010;160:785-94.
41. Navaneethan SD, Hegbrant J, Strippoli GF. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2011;20:146-52.
42. Fellström B, Holdaas H, Jardine AG, et al; AURORA Study Group. Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin 2009;25:271-85.
43. Palmer BF, Fenves AZ. Optimizing blood pressure control in patients with chronic kidney disease. Proc (Bayl Univ Med Cent) 2010;23:239-45.
44. Jafar TH, Stark PC, Schmid CH, et al. for the AIPRD Study Group: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003;139:244-52.
45. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 2006;1:1054-65.
46. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al; GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18:781-8. (Pubitemid 39530090)
47. Bakris GL, Sarafidis PA, Weir MR, et al; ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81.
48. Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in highrisk patients. N Engl J Med. 2008;359:2417-28.
49. Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008;58:623-30. (Pubitemid 351294901)
50. Athyros VG, Elisaf M, Papageorgiou AA, et al; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99. (Pubitemid 38401873)
51. Daskalopoulou SS, Mikhailidis DP, Athyros VG, et al. Fenofibrate and losartan. Ann Rheum Dis 2004;63:469-70.
52. Karagiannis A, Mikhailidis DP, Athyros VG, et al. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin Ther Targets 2007;11:191-205. (Pubitemid 46193915)
53. Hoieggen A, Alderman MH, Kjeldsen SE, et al. LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9. (Pubitemid 38251080)
54. Daskalopoulou SS, Athyros VG, Elisaf M, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66:1714-15. (Pubitemid 39298414)
55. Katsiki N, Athyros VG, Karagiannis A, et al. Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A relationship with implications for vascular risk? Curr Vasc Pharmacol 2011 Mar 10. [Epub ahead of print].
56. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266